IDEXX Laboratories, Inc.
$580.27
▲
1.98%
2026-04-22 10:12:13
www.idexx.com
NMS: IDXX
Explore IDEXX Laboratories, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$46.26 B
Current Price
$580.27
52W High / Low
$769.98 / $402.85
Stock P/E
44.49
Book Value
$20.14
Dividend Yield
—
ROCE
61.76%
ROE
66.2%
Face Value
—
EPS
$13.08
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
11,000
Beta
1.72
Debt / Equity
60.83
Current Ratio
1.23
Quick Ratio
0.9
Forward P/E
34.28
Price / Sales
10.42
Enterprise Value
$45.62 B
EV / EBITDA
30.31
EV / Revenue
10.6
Rating
Buy
Target Price
$742.54
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | GRAIL, Inc. | $51.2 | — | $2.1 B | — | -18.79% | -16.07% | $118.84 / $25.56 | $63.92 |
| 2. | bioAffinity Technologies, Inc. | $2.69 | — | $12.87 M | — | -131.93% | -3.02% | $17.44 / $0.69 | $1.62 |
| 3. | Advanced Biomed Inc. | $5 | 1.49 | $6.55 M | — | — | 80.18% | $48.8 / $3.61 | $8.76 |
| 4. | BillionToOne, Inc. | $86.97 | 489.81 | $3.65 B | — | 2.74% | 2.3% | $138.7 / $61.96 | $10.48 |
| 5. | Castle Biosciences, Inc. | $25.16 | — | $744.77 M | — | -8.4% | -5.21% | $44.28 / $14.59 | $15.86 |
| 6. | Waters Corporation | $332.95 | 30.93 | $32.76 B | — | 20.92% | 29.28% | $414.15 / $275.05 | $43.01 |
| 7. | Danaher Corporation | $189.21 | 37.67 | $133.79 B | 0.82% | 6.12% | 7.05% | $242.8 / $180.03 | $74.32 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 1.09 B | 1.11 B | 1.11 B | 998.43 M | 954.29 M |
| Operating Profit | 315.61 M | 354.85 M | 373.05 M | 316.53 M | 261.69 M |
| Net Profit | 248.19 M | 274.61 M | 293.99 M | 242.68 M | 216.15 M |
| EPS in Rs | 3.12 | 3.46 | 3.7 | 3.06 | 2.72 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 4.3 B | 3.9 B | 3.66 B | 3.37 B |
| Operating Profit | 1.36 B | 1.13 B | 1.1 B | 898.76 M |
| Net Profit | 1.06 B | 887.87 M | 845.04 M | 679.09 M |
| EPS in Rs | 13.34 | 11.18 | 10.64 | 8.55 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 3.35 B | 3.29 B | 3.26 B | 2.75 B |
| Total Liabilities | 1.75 B | 1.7 B | 1.78 B | 2.14 B |
| Equity | 1.61 B | 1.6 B | 1.48 B | 608.74 M |
| Current Assets | 1.41 B | 1.4 B | 1.5 B | 1.1 B |
| Current Liabilities | 1.15 B | 1.07 B | 951.55 M | 1.24 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 1.18 B | 929 M | 906.51 M | 542.98 M |
| Investing CF | -136.24 M | -207.06 M | -125.25 M | -195.35 M |
| Financing CF | -1.16 B | -878.07 M | -442 M | -370.94 M |
| Free CF | 1.04 B | 798.08 M | 772.88 M | 384.15 M |
| Capex | -138.23 M | -130.92 M | -133.63 M | -158.84 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 6.46% | 8.72% | — | — |
| Earnings Growth % | 5.07% | 24.44% | — | — |
| Profit Margin % | 22.78% | 23.08% | 20.17% | — |
| Operating Margin % | 28.95% | 29.97% | 26.69% | — |
| Gross Margin % | 61.04% | 59.82% | 59.52% | — |
| EBITDA Margin % | 32.61% | 33.26% | 30.05% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.